Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection.
Alcaide
A J
AJ
Barrera
M V
MV
Habicheyn
S
S
López
N
N
Mendiola
M V
MV
Herrera
E
E
D000328:Adult; D004314:Down Syndrome / Q000150:complications*; D000068800:Etanercept; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept